CHOP’s Neuromuscular Program Named a Certified Duchenne Care Center (CDCC) by Parent Project Muscular Dystrophy (PPMD)

Duchenne muscular dystrophy (DMD) is a genetic condition in which an individual lacks a functional version of the dystrophin gene, which helps muscles stay healthy. As a result, their muscles break down and are, over time, replaced with fatty deposits. This leads to a host of symptoms, from loss of mobility to life-threatening heart and respiratory problems to low life expectancy.

While there is no known cure for DMD, experts in the Neuromuscular Program at Children's Hospital of Philadelphia (CHOP) are active participants in clinical trials, working to create new and innovative treatments for neuromuscular disorders. For these efforts, the program was recently named a Certified Duchenne Care Center (CDCC) by the Parent Project Muscular Dystrophy (PPMD). This certification is given to programs that maintain the highest standards in clinical and sub-specialty services, rapidly apply new evidence-based knowledge, and comply with CDC clinical care standards. CHOP is also the first center to receive the PPMD’s newly established Clinical Research Designation — recognizing excellence in both clinical care and research. This certification highlights CHOP’s long-standing commitment to providing world-class care and advancing clinical research for individuals living with muscular dystrophy.